Wall Street analysts expect Medpace Holdings Inc (NASDAQ:MEDP) to report earnings of $0.71 per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Medpace’s earnings, with the highest EPS estimate coming in at $0.75 and the lowest estimate coming in at $0.64. Medpace posted earnings of $0.67 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 6%. The business is scheduled to issue its next quarterly earnings results after the market closes on Monday, October 28th.
According to Zacks, analysts expect that Medpace will report full-year earnings of $2.91 per share for the current financial year, with EPS estimates ranging from $2.88 to $2.95. For the next year, analysts anticipate that the company will post earnings of $3.31 per share, with EPS estimates ranging from $3.16 to $3.50. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Medpace.
Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, July 29th. The company reported $0.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.63 by $0.18. The business had revenue of $214.10 million for the quarter, compared to analyst estimates of $200.99 million. Medpace had a net margin of 11.28% and a return on equity of 17.65%. The company’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same period last year, the firm posted $0.61 earnings per share.
MEDP has been the topic of a number of research reports. BidaskClub lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $85.00 price objective on the stock in a research report on Wednesday. SunTrust Banks lifted their price objective on shares of Medpace to $85.00 and gave the company a “buy” rating in a research report on Wednesday, July 31st. Credit Suisse Group raised their target price on Medpace from $65.00 to $77.00 and gave the company an “outperform” rating in a report on Tuesday, July 30th. Finally, ValuEngine downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $77.25.
In related news, General Counsel Stephen P. Ewald sold 8,000 shares of the stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $77.30, for a total value of $618,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jesse J. Geiger sold 7,200 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $78.03, for a total value of $561,816.00. Following the sale, the chief financial officer now directly owns 40,948 shares of the company’s stock, valued at $3,195,172.44. The disclosure for this sale can be found here. Company insiders own 24.20% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Rhumbline Advisers raised its stake in shares of Medpace by 4.9% during the 3rd quarter. Rhumbline Advisers now owns 81,345 shares of the company’s stock worth $6,836,000 after purchasing an additional 3,813 shares in the last quarter. State of New Jersey Common Pension Fund D purchased a new stake in shares of Medpace during the 3rd quarter worth about $3,084,000. Alberta Investment Management Corp purchased a new stake in shares of Medpace during the 3rd quarter worth about $2,168,000. Avitas Wealth Management LLC purchased a new stake in shares of Medpace during the 3rd quarter worth about $579,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Medpace by 32.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,848 shares of the company’s stock worth $155,000 after purchasing an additional 452 shares in the last quarter. 83.42% of the stock is owned by institutional investors.
Shares of MEDP traded down $0.28 during mid-day trading on Wednesday, reaching $74.69. 224,984 shares of the company’s stock were exchanged, compared to its average volume of 489,470. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.66 and a quick ratio of 0.66. The stock has a market capitalization of $2.73 billion, a PE ratio of 28.84, a price-to-earnings-growth ratio of 2.09 and a beta of 1.55. The business’s fifty day simple moving average is $81.42 and its 200-day simple moving average is $68.13. Medpace has a 52-week low of $45.88 and a 52-week high of $86.71.
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Featured Story: What is Cost of Debt?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.